Medical Center Dr. Kalchev Ltd.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The clinical trial activity at Medical Center Dr. Kalchev Ltd. includes a strong focus on cardiovascular diseases, especially atherosclerotic cardiovascular disease, hypertension, and broader high cardiovascular risk populations. These studies are designed to assess new approaches that may improve heart and blood vessel health, lower major cardiovascular events, and support better long-term prevention.
- Testing new treatments for atherosclerotic cardiovascular disease
- Evaluating strategies to reduce cardiovascular morbidity and mortality
- Studying blood pressure control in hypertension and high-risk patients
Overall, this research area is centered on improving treatment effectiveness and reducing serious complications such as heart attack, stroke, and cardiovascular death.
Digestive System Diseases
This site also supports research in digestive system diseases, with studies involving alcoholic liver disease and metabolic dysfunction-associated steatotic liver disease as well as related forms of liver inflammation and injury. The trials are aimed at understanding how to better manage liver disease and evaluate therapies that may improve liver health in patients with metabolic or alcohol-related conditions.
- Investigating treatment options for alcoholic liver disease
- Exploring therapies for MASLD and MASH
- Assessing approaches that may improve liver function and disease control
These studies reflect an effort to advance care for chronic liver conditions where effective management remains an important clinical need.
Nutritional and Metabolic Diseases
Clinical research in nutritional and metabolic diseases at this hospital/clinic includes studies of severe hypertriglyceridemia, obesity, and metabolic risk linked to cardiovascular disease. The trials are focused on testing new therapies and measuring whether they can improve lipid levels, weight-related risk, and overall metabolic health.
- Evaluating therapies for severe hypertriglyceridemia
- Studying patients with obesity and atherosclerotic cardiovascular disease
- Assessing treatment effects on lipid metabolism and related risk factors
This area highlights research aimed at reducing metabolic complications that often contribute to broader cardiovascular and liver disease burden.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
The site’s trial portfolio also touches on broader congenital, hereditary, and neonatal diseases and abnormalities through work that intersects with inherited and long-term metabolic risk. While the main emphasis remains on adult cardiometabolic conditions, this therapeutic area reflects interest in disease mechanisms and treatment responses that may have a genetic or lifelong component.
- Exploring inherited factors that influence cardiovascular risk
- Studying disease patterns that may be linked to metabolic abnormalities
- Supporting research into conditions with a hereditary component
At Medical Center Dr. Kalchev Ltd., this contributes to a wider research profile that connects metabolic, cardiovascular, and liver-related disease areas.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1Alnylam Pharmaceuticals Inc.1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Ionis Pharmaceuticals Inc.2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 476 other sites in Bulgaria
Therapeutic Area Benchmark — Bulgaria
Select a therapeutic area to compare against other sites in Bulgaria.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Bulgaria
Market Share
Country: Bulgaria
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medical Center Dr. Kalchev Ltd.
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impactof Maridebart Cafraglutide on Cardiovascular Outcomes in Participants with Atherosclerotic Cardiovascular Disease and Overweight or Obesity (MARITIME-CV) | Amgen Inc. | Phase III | Recruiting | Oct 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Isis 678354 Sodium Salt | 2 | Unknown | 2022-03-08 | 2023-07-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.